Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

NCT04778397 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

258

Enrollment

INDUSTRY

Sponsor class

Stopped Study discontinued due to futility.

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Magrolimab
DRUG: Venetoclax
DRUG: Azacitidine
DRUG: Cytarabine
DRUG: Daunorubicin
DRUG: Idarubicin
DRUG: Steroidal Eye Drops

Sponsor

Gilead Sciences